Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Inhibidores estables de la vía de la 5-lipooxigenasa para el tratamiento no tóxico del asma y el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20170324001
Publicado:
03/04/2017
Caducidad:
03/04/2018
Resumen:
Una universidad alemana ha desarrollado una enzima 5-lipooxigenasa que cataliza la transformación de ácido araquidónico en leucotrienos biológicamente activos. Estos son mediadores de señalización celular implicados en enfermedades inflamatorias, como asma y diversos tipos de cáncer. Los inhibidores de 5-lipooxigenasa no son tóxicos y tienen una destacada estabilidad biológica. Los investigadores han descubierto que la introducción de carboranos no influye en el potencial inhibitorio de la vía de la 5-LO pero aumenta de forma clara y selectiva la citotoxicidad para células cancerígenas, demostrado por ensayos con líneas celulares de cáncer de colon y melanoma invasivo. La universidad busca socios con el fin de realizar los estudios preclínicos y clínicos y establecer acuerdos comerciales con asistencia técnica.

Details

Tittle:
Stable inhibitors of the 5-lipoxygenase pathway for non-toxic treatment of asthma and cancer
Summary:
A German university developed a 5-lipoxygenase enzyme that catalyses the conversion of arachidonic acid to biologically active leukotrienes. These are cellular signalling mediators involved in inflammatory diseases, such as asthma and diverse types of cancer. The 5-lipoxygenase inhibitors are non-toxic and have remarkable biological stability. The university is looking for partners to carry out preclinical and clinical studies under commercial agreement with technical assistance.
Description:
The department for biotechnology and biomedicine of a famous Germany university was found in 2003. The department promotes the networking of research within the university while simultaneously utilizing emerging interdisciplinary synergies.

Researchers have investigated the substitution of metabolisable phenyl rings of lipoxygenase inhibitors by metabolically stable boron compounds, namely, carboranes (C2B10H12). Carboranes are icosahedral boron clusters in which two boron atoms are replaced by carbon atoms. They are non-toxic, have remarkable biological stability, and the carbon atoms can be functionalised easily and selectively. The researchers found out that the introduction of carboranes does not influence the inhibitory potential for the 5-LO pathway, but strongly and selectively increases the cytotoxicity for cancer cells, demonstrated by tests with invasive melanoma and colon cancer cell lines. Mice with colon adenocarcinoma show an improved response to the investigated compounds (clear reduction of tumour) and show no acute toxicity.

The next steps for the further development are the competent performance of preclinical and clinical studies, for which are partners (from industry or R-Y-D institutions) sought for under commercial agreement with technical assistance.
Advantages and Innovations:
The new LO-inhibitors can be synthesized easily and fast in three steps. They are non-toxic, have remarkable biological stability, and the carbon atoms can be functionalised easily and selectively.
Potential Applications:
- Treatment of 5-LO dependent tumours,
- Tumour imaging
- Boron neutron capture therapy (BNCT).
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how

Partner sought

Type and Role of Partner Sought:
There is a partner sought from industry or R-Y-D institution to carry out preclinical or clinical studies.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos